Gsa Capital Partners LLP Exelixis, Inc. Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

A detailed history of Gsa Capital Partners LLP transactions in Exelixis, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 11,708 shares of EXEL stock, worth $395,964. This represents 0.02% of its overall portfolio holdings.

Number of Shares

11,708

Previous 64,691 81.9%

Holding current value

$395,964

Previous $1.45 Million 79.09%

% of portfolio

0.02%

Previous 0.1%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$21.96 - $27.6 $1.16 Million - $1.46 Million	-52,983 Reduced 81.9%	11,708 $304,000
Q2 2024 Aug 15, 2024	BUY	$20.34 - $23.73 $217,841 - $254,148	10,710 Added 19.84%	64,691 $1.45 Million
Q1 2024 May 03, 2024	BUY	$20.17 - $23.93 $1.09 Million - $1.29 Million	53,981 New	53,981 $1.28 Million
Q3 2023 Nov 15, 2023	BUY	$19.04 - $22.74 $515,812 - $616,049	27,091 Added 117.65%	50,117 $1.1 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $418,382 - $471,572	23,026 New	23,026 $440,000
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $1.51 Million - $1.76 Million	-101,126 Reduced 89.28%	12,145 $195,000
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $882,736 - $1.25 Million	56,297 Added 98.81%	113,271 $1.78 Million
Q2 2022 Aug 09, 2022	BUY	$17.44 - $23.16 $825,557 - $1.1 Million	47,337 Added 491.2%	56,974 $1.19 Million
Q1 2022 May 11, 2022	BUY	$17.03 - $22.67 $164,118 - $218,470	9,637 New	9,637 $218,000
Q2 2021 Aug 05, 2021	SELL	$17.95 - $25.56 $264,116 - $376,089	-14,714 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$20.53 - $25.22 $302,078 - $371,087	14,714 New	14,714 $332,000
Q2 2020 Aug 11, 2020	SELL	$16.46 - $27.42 $246,718 - $410,998	-14,989 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$14.46 - $21.8 $15,746 - $23,740	1,089 Added 7.83%	14,989 $258,000
Q4 2019 Feb 12, 2020	SELL	$15.15 - $18.89 $92,627 - $115,493	-6,114 Reduced 30.55%	13,900 $245,000
Q3 2019 Nov 12, 2019	BUY	$17.68 - $22.65 $118,314 - $151,573	6,692 Added 50.23%	20,014 $354,000
Q2 2019 Aug 06, 2019	BUY	$18.93 - $24.75 $23,435 - $30,640	1,238 Added 10.24%	13,322 $285,000
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $155,349 - $196,247	-7,926 Reduced 39.61%	12,084 $288,000
Q4 2018 Feb 12, 2019	BUY	$13.65 - $21.8 $273,136 - $436,218	20,010 New	20,010 $394,000
Q3 2018 Nov 13, 2018	SELL	$15.87 - $22.4 $394,671 - $557,065	-24,869 Closed	0 $0
Q2 2018 Aug 09, 2018	SELL	$18.56 - $22.45 $2.29 Million - $2.77 Million	-123,500 Reduced 83.24%	24,869 $535,000
Q1 2018 May 11, 2018	BUY	$22.15 - $31.89 $105,766 - $152,274	4,775 Added 3.33%	148,369 $3.29 Million
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $2.14 Million - $2.73 Million	88,343 Added 159.89%	143,594 $4.37 Million
Q3 2017 Nov 20, 2017	BUY	$23.35 - $29.24 $1.29 Million - $1.62 Million	55,251	55,251 $1.34 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Exelixis, Inc. Transaction History